CRISPR Gene Editing Market by Product, Services, Technology, Application, End User

KEY MARKET STATISTICS
Base Year [2023]	USD 3.57 billion
Estimated Year [2024]	USD 4.18 billion
Forecast Year [2030]	USD 7.72 billion
CAGR (%)	11.65%

The FPNV Positioning Matrix is pivotal in evaluating the CRISPR Gene Editing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CRISPR Gene Editing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the CRISPR Gene Editing Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Beam Therapeutics Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Biorad, Calyxt, Inc., Caribou Biosciences, Inc., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., F. Hoffmann-La Roche AG, Hera Biolabs, Horizon Discovery Group Plc, Inscripta, Inc., Integrated Dna Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group, Mammoth Biosciences, Merck KGaA, Qiagen NV, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the CRISPR Gene Editing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Enzymes
- Kits
- Libraries
Services
- Cell Line Engineering
- gRNA design
- Screening
Technology
- CRISPR
- TALEN
- ZFN
Application
- Cell Line Engineering
- Diagnostics
- Drug Discovery
- Gene-modified Cell Therapy
- Genetic Engineering
End User
- Academics & Government Institutes
- Biotechnology & Pharma Companies
- Contract Research Organizations
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the CRISPR Gene Editing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the CRISPR Gene Editing Market?

3. What are the technology trends and regulatory frameworks in the CRISPR Gene Editing Market?

4. What is the market share of the leading vendors in the CRISPR Gene Editing Market?

5. Which modes and strategic moves are suitable for entering the CRISPR Gene Editing Market?

Product Code: MRR-5C6F41F5AFAA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. CRISPR Gene Editing Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising number of chronic diseases and genetic disorders
  - 5.1.1.2. Adoption of CRISPR gene editing to improve food security
  - 5.1.1.3. Government initiatives to propel CRISPR research and investment by major players
- 5.1.2. Restraints
  - 5.1.2.1. High cost of CRISPR therapies
- 5.1.3. Opportunities
  - 5.1.3.1. Adoption of CRISPR editing tools for personalized medicine and cancer therapeutics
  - 5.1.3.2. Utilization of CRISPR to propel space travel
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations concerning genome editing and ethical concerns
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. CRISPR Gene Editing Market, by Product

6.1. Introduction
6.2. Enzymes
6.3. Kits
6.4. Libraries

7. CRISPR Gene Editing Market, by Services

7.1. Introduction
7.2. Cell Line Engineering
7.3. gRNA design
7.4. Screening

8. CRISPR Gene Editing Market, by Technology

8.1. Introduction
8.2. CRISPR
8.3. TALEN
8.4. ZFN

9. CRISPR Gene Editing Market, by Application

9.1. Introduction
9.2. Cell Line Engineering
9.3. Diagnostics
9.4. Drug Discovery
9.5. Gene-modified Cell Therapy
9.6. Genetic Engineering

10. CRISPR Gene Editing Market, by End User

10.1. Introduction
10.2. Academics & Government Institutes
10.3. Biotechnology & Pharma Companies
10.4. Contract Research Organizations

11. Americas CRISPR Gene Editing Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific CRISPR Gene Editing Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa CRISPR Gene Editing Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. AstraZeneca plc
- 15.1.2. Beam Therapeutics Inc.
- 15.1.3. Beckman Coulter, Inc.
- 15.1.4. Bio-Rad Laboratories, Inc.
- 15.1.5. Biorad
- 15.1.6. Calyxt, Inc.
- 15.1.7. Caribou Biosciences, Inc.
- 15.1.8. CRISPR Therapeutics AG
- 15.1.9. Danaher Corporation
- 15.1.10. Editas Medicine, Inc.
- 15.1.11. F. Hoffmann-La Roche AG
- 15.1.12. Hera Biolabs
- 15.1.13. Horizon Discovery Group Plc
- 15.1.14. Inscripta, Inc.
- 15.1.15. Integrated Dna Technologies, Inc.
- 15.1.16. Intellia Therapeutics, Inc.
- 15.1.17. Lonza Group
- 15.1.18. Mammoth Biosciences
- 15.1.19. Merck KGaA
- 15.1.20. Qiagen NV
- 15.1.21. Thermo Fisher Scientific Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing